Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SAT1 | P21673 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26465383 | 0.84 | CYP2C19 (0.50) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL5932913 | 0.82 | CYP2C19 (0.53) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL21106247 | 0.81 | KDM4E (0.36) | KDM4ERECQLTSHR | |
| SCHEMBL24925547 | 0.81 | TSHR (0.33) | KDM4ERECQLTSHR | |
| SCHEMBL24673499 | 0.81 | KDM4E (0.31) | KDM4E | |
| SCHEMBL6236876 | 0.79 | CYP2C19 (0.47) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL25815825 | 0.79 | KDM4E (0.30) | CYP2C19CYP1A2KDM4E | |
| SCHEMBL23341229 | 0.78 | HRH3 (0.32) | — | |
| SCHEMBL23945319 | 0.78 | CYP2C19 (0.43) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL26018451 | 0.78 | HTT (0.41) | MEN1KMT2ATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2C19 3990/4885MEN1 4055/4885GLA 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.